The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab.
Brandon George Smaglo
No relevant relationships to disclose
Hongkun Wang
No relevant relationships to disclose
Kenneth Steadman
No relevant relationships to disclose
Joseph Murray
No relevant relationships to disclose
Michael Pishvaian
No relevant relationships to disclose
Aiwu Ruth He
No relevant relationships to disclose
Jimmy J. Hwang
No relevant relationships to disclose
Deepa Suresh Subramaniam
No relevant relationships to disclose
John F. Deeken
Research Funding - Novartis
Louis M. Weiner
No relevant relationships to disclose